Viewing Study NCT02810418


Ignite Creation Date: 2025-12-25 @ 4:38 AM
Ignite Modification Date: 2026-03-01 @ 6:11 AM
Study NCT ID: NCT02810418
Status: COMPLETED
Last Update Posted: 2022-03-15
First Post: 2016-06-22
Is NOT Gene Therapy: True
Has Adverse Events: True

Brief Title: Mesothelin-Targeted Immunotoxin LMB-100 Alone or in Combination With Nab-Paclitaxel in People With Previously Treated Metastatic and/or Locally Advanced Pancreatic Ductal Adenocarcinoma and Mesothelin Expressing Solid Tumors
Sponsor: National Cancer Institute (NCI)
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Neoplasms View
None Pancreatic Neoplasms View
Keywords:

Keywords

Keyword Brief Keyword Text View
None Immunotoxin View
None Mesothelin View
None Antibody-based Therapeutics View
None Advanced Cancer View